What does tumor mutational burden mean for HER2-Low Breast Cancer immunotherapy

Tumor Mutational Burden (TMB) and HER2-Low Breast Cancer Immunotherapy

I appreciate this question because TMB is an important emerging biomarker that's getting more attention in breast cancer treatment planning. Let me break down what this means in practical terms.

What is Tumor Mutational Burden?

Tumor mutational burden (TMB) is a measure of how many mutations (genetic changes) exist in your cancer cells. Think of it as counting the number of "spelling errors" in your tumor's genetic code. A higher TMB means more mutations—which can actually be beneficial in certain treatment contexts.

TMB is typically measured using next-generation sequencing (NGS), a sophisticated genetic test that reads through your tumor's DNA and counts these mutations. The standard threshold doctors use is ≥10 mutations per megabase (mut/Mb), which is considered "TMB-high" (TMB-H).

Why TMB Matters for Immunotherapy

Here's the clinical reasoning: Immunotherapy works by "waking up" your immune system to recognize and attack cancer cells. The more mutations a cancer has, the more "foreign" it looks to your immune system—like having more red flags that say "this doesn't belong here." This makes it easier for immunotherapy drugs to help your immune cells identify and destroy the cancer.

According to NCCN Guidelines for Invasive Breast Cancer, TMB-H (≥10 mut/Mb) is recognized as a biomarker associated with potential response to immunotherapy, specifically pembrolizumab, which is an FDA-approved checkpoint inhibitor.

TMB in HER2-Low Breast Cancer Specifically

Here's where it gets important for your situation: HER2-low breast cancer is a relatively newer classification that sits between HER2-negative and HER2-positive disease. The treatment landscape for HER2-low breast cancer has expanded significantly with newer targeted therapies like trastuzumab deruxtecan (T-DXd), which targets low levels of HER2 expression.

However, TMB assessment becomes relevant when:

• Your cancer doesn't respond well to standard hormone therapy or HER2-targeted approaches
• Your doctor is considering immunotherapy as an option
• You have other biomarkers (like MSI-H/dMMR—mismatch repair deficiency) that might suggest immunotherapy could help

According to NCCN Guidelines, pembrolizumab is recommended as a Category 2A option for patients with TMB-H tumors (≥10 mut/Mb) who have progressed on prior treatment and have no satisfactory alternative options.

What This Means for Your Care

Important context: TMB-H alone doesn't automatically mean immunotherapy is right for you. Your oncologist will consider:

1. Your complete clinical picture - stage, prior treatments, other biomarkers
2. Your specific HER2-low subtype - whether it's hormone receptor-positive or negative
3. Available alternatives - newer HER2-targeted therapies may be preferred first
4. Your overall health - immunotherapy has different side effects than other treatments

Questions to Ask Your Oncologist

If TMB testing is being considered or has been done, these questions can help guide your discussion:

1. "Has my tumor been tested for TMB, and if so, what was my result?"
2. "Given my HER2-low status and TMB result, what treatment options does this open up for me?"
3. "Is immunotherapy being recommended, and if so, how does it compare to other options like HER2-targeted therapy?"
4. "What other biomarkers should I know about that might affect treatment decisions?"
5. "If I pursue immunotherapy, what side effects should I watch for, and how will you monitor my response?"

Key Takeaway

TMB is an emerging tool that helps doctors understand whether your immune system might respond well to immunotherapy. For HER2-low breast cancer, it's one piece of the puzzle—but not the whole picture. Your oncologist will weigh TMB results alongside your HER2 status, hormone receptor status, prior treatments, and other clinical factors to determine the best approach for YOUR specific situation.

---

Sources:

• NCCN Guidelines for Invasive Breast Cancer (Version 5.2025) - TMB-H biomarker recommendations
• NCCN Guidelines for Invasive Breast Cancer - Pembrolizumab as Category 2A option for TMB-H disease

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.